Rayford A, Rao J S, Festoff B W
Neurobiology Research Laboratory, Department of Veterans Affairs Medical Center, Kansas City, Missouri 64128.
J Neurochem. 1992 Jan;58(1):88-94. doi: 10.1111/j.1471-4159.1992.tb09281.x.
Cerebrospinal fluid (CSF) from 20 male patients with nonneurologic disease (age 64.5 +/- 2.8 SEM) was analyzed for the presence of the serpin alpha 1-antichymotrypsin (alpha 1-ACT). A chymotrypsin-specific chromogenic substrate (succinyl-Ala-Ala-Pro-Phe-p-nitroanilide) was used to examine the CSF samples. All CSF samples showed inhibitory activity ranging from 45 to 80% inhibition. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of the samples revealed the presence of a 68-kDa protein migrating identical to authentic human plasma alpha 1-ACT. Complex formation was performed with iodinated bovine chymotrypsin for several representative CSF samples having the highest chymotrypsin inhibitory activity. Comparison was made with complex formation performed with commercially available authentic human plasma alpha 1-ACT. These studies showed the formation of complexes at 37 degrees C, regardless of whether the sample was subsequently boiled or not. In the case of CSF, two complex bands, mass smaller than with plasma alpha 1-ACT, were formed at the lower temperature whereas a single higher Mr band was formed when the samples were boiled. To determine whether cleavage of the serpin occurred, these studies were repeated using human neutrophil cathepsin G as target protease. A complex of approximately 90 kDa was formed with human alpha 1-ACT under these same conditions. alpha 1-ACT has been detected in senile amyloid plaques in brains of Alzheimer's disease patients, the only plasma serine protease inhibitor localized to these structures. Another serpin, protease nexin I, is also found in these plaques, but this inhibitor does not circulate in plasma.(ABSTRACT TRUNCATED AT 250 WORDS)
对20名患有非神经系统疾病的男性患者(年龄64.5±2.8标准误)的脑脊液(CSF)进行分析,以检测丝氨酸蛋白酶抑制剂α1 -抗糜蛋白酶(α1 - ACT)的存在。使用一种对糜蛋白酶具有特异性的显色底物(琥珀酰 - 丙氨酸 - 丙氨酸 - 脯氨酸 - 苯丙氨酸 - 对硝基苯胺)来检测脑脊液样本。所有脑脊液样本均显示出45%至80%的抑制活性。对样本进行十二烷基硫酸钠 - 聚丙烯酰胺凝胶电泳分析,结果显示存在一种68 kDa的蛋白质,其迁移情况与 authentic human plasma alpha 1 - ACT相同。对几种具有最高糜蛋白酶抑制活性的代表性脑脊液样本,用碘化牛糜蛋白酶进行复合物形成实验。并与使用市售 authentic human plasma alpha 1 - ACT进行的复合物形成实验作比较。这些研究表明,无论样本随后是否煮沸,在37℃时都会形成复合物。对于脑脊液,在较低温度下会形成两条复合物带,其分子量比血浆α1 - ACT的小,而当样本煮沸时会形成一条分子量更高的带。为了确定丝氨酸蛋白酶抑制剂是否发生裂解,使用人中性粒细胞组织蛋白酶G作为靶蛋白酶重复这些研究。在相同条件下,人α1 - ACT形成了一个约90 kDa的复合物。在阿尔茨海默病患者大脑的老年淀粉样斑块中检测到了α1 - ACT,它是唯一定位于这些结构的血浆丝氨酸蛋白酶抑制剂。在这些斑块中还发现了另一种丝氨酸蛋白酶抑制剂,即蛋白酶nexin I,但这种抑制剂不在血浆中循环。(摘要截短至250字)